Please login to the form below
Data by
2
Revenue 2014Pfizer
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Pfizer's 2013 sales performance.
Sanofi continues pharma's trend of ditching the corporate blog
But in the case of J&J’s previously long-running JnJBTW blog visitors are redirected to the homepage of the firm’s corporate website, while Pfizer’s Think Science blog
Meet the Judges
Following a move to Pfizer, he initially worked in health economics and outcomes before leading payer and market access strategy and tactics for several blockbuster brands alongside joint working initiatives with ... Within Pfizer he also worked across
EP downgrades long-term sales projections for pharma
As it stands Novartis, Pfizer and Roche are competing head to head for the crown of being the largest company by worldwide prescription sales in 2022, with Novartis seeming to have
Asian patient groups give pharma above average marks for reputation
PatientView’s 2016 Corporate Reputation of Pharma Companies survey covers the efforts of 16 global pharma companies including Pfizer- which was ranked the most familiar to the Asian patient groups.
NICE rejects Pfizer's antibody drug for leukaemia
NICE rejects Pfizer's antibody drug for leukaemia. Trial shows no survival benefit from Besponsa compared to current treatment. ... The National Institute for Health and Care Excellence (NICE) has turned down Pfizer’s leukaemia drug Besponsa in draft
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| US revenue 2014 |
|---|
| 1: Gilead Sciences |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Roche |
| 5: Novartis |
| 6: Amgen |
| 7: Merck & Co. |
| 8: Sanofi |
| 9: AbbVie |
| 10: Actavis |
| 11: AstraZeneca |
| 12: GlaxoSmithKline |
| 13: Lilly |
| 14: Bristol-Myers Squibb |
| 15: Novo Nordisk |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| CNS revenue 2014 |
|---|
| 1: Pfizer |
| 2: Biogen Idec |
| 3: Novartis |
| 4: Otsuka |
| 5: Teva |
| 6: Johnson & Johnson |
| 7: Lilly |
| 8: Merck KGaA |
| 9: AstraZeneca |
| 10: Shire |
| 11: Bristol-Myers Squibb |
| 12: UCB |
| 13: Lundbeck |
| 14: Eisai |
| 15: GlaxoSmithKline |
| 16: Sanofi |
| 17: Mylan |
| 18: Indivior |
| 19: Actavis |
| 20: Bayer |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
| Biologic revenue 2014 |
|---|
| 1: Roche |
| 2: Amgen |
| 3: Novo Nordisk |
| 4: AbbVie |
| 5: Sanofi |
| 6: Johnson & Johnson |
| 7: Pfizer |
| 8: Merck & Co. |
| 9: Lilly |
| 10: Biogen Idec |
| 11: Merck KGaA |
| 12: GlaxoSmithKline |
| 13: Bristol-Myers Squibb |
| 14: Novartis |
| 15: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- 6-12 MONTH FREELANCE OPPORTUNITY - ACCOUNT DIRECTOR or SENIOR AC...
-
SUPERB DAY RATE AVAILABLE
- Senior Director, Healthcare PR, Home Counties
-
Competitive
-
Principal Medical Writer
-
Great salary and benefits
- Account Manager, Healthcare PR, Global and UK
-
£33, 000 – £40, 000
-
Scientific Director
-
£70, 000 - £85, 000
- Account Director - Healthcare Advertising - London
-
£50000 - £68000
- Senior Account Manager – Healthcare PR
-
Salary TBC
- Senior Corporate Communications Manager
-
Competitive Salary
-
Senior Medical Writer
-
Great salary and benefits
-
Brand Communications Manager
-
A competitive salary plus bonus
- FREELANCE *Client Service/ Project Manager*
-
Competitive Salary
- Account Manager, Medical Communications
-
£30, 000-£40, 000
-
Account Director - Med Comms
-
Great salary and benefits
-
Director – Healthcare PR/ Policy
-
Salary TBC
-
*Multi-Channel Creative Designer*
-
Competitive Salary
-
Head of Marketing Insulin
-
Competitive Salary
- Account Director or Senior Account Director, Healthcare Advertis...
-
£55, 000 - £65, 000 benefits
-
*Design Manager*
-
Competitive Salary
Subscribe to our email news alerts
- Sanofi continues pharma's trend of ditching the corporate blog
- Bayer wins FDA approval for MS electronic autoinjector and app
- Warning sounded on pharma's long-term sales prospects
- Facing the new wave of biosimilars
- Sandoz joins Europe's MabThera biosimilar push
- FDA panel backs CV claims for Novo Nordisk's Victoza
- The new pharma marketing playbook
- PEGASUS SHOWREEL 2017
- Alzheon says data backs potential of Alzheimer's candidate
- Shift to value-based medicine will boost mHealth uptake
- Ashfield to host global webinar on Patient Service Team on 10 July
- Pharma needs to evolve from customer-centricity to stakeholder-centricity
PMHub
WE Communications
WE’s global and European healthcare hub is based in London, and works with experienced teams across the globe; teams encompassing...
Latest intelligence
- The new pharma marketing playbook
- Learn about the 5 areas that must be in your pharma marketing playbook...
- Pharma needs to evolve from customer-centricity to stakeholder-centricity
- Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
- 5 health behavioural factors to incorporate in your marketing
- Achieve real health behaviour change by including these elements in your pharmaceutical marketing....
Quick links
Infographics
